Home
Acelyrin, Inc.

Acelyrin, Inc. Market Share Analysis for May 2026

building a sustainable biopharma company that invests in, develops and commercializes life-changing innovative therapeutics and transformative medicines.

Health > Biotechnology and Pharmaceuticals

Domainacelyrin.com

Year Founded2020

Employees51 - 200

Annual Revenue--

Acelyrin, Inc.

Acelyrin, Inc. (including company regionals)

acelyrin.com

See more website traffic and engagement information

Total visits to Acelyrin, Inc.'s top domains

Understand Acelyrin, Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Acelyrin, Inc.'s top domains

Analyze Acelyrin, Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Acelyrin, Inc.'s top domains

See how Acelyrin, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Acelyrin, Inc. top competitors by domain

Top similar sites in May 2026, ranked by their affinity

biopharmadive.comCompany NameBioPharma DiveEmployees51 - 200HQUnited States, Washington, WashingtonAnnual revenue$10M - $15MTotal visits176.3KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Acelyrin, Inc.

These are the website technologies, by industry, used by Acelyrin, Inc. top domains

Advertising (2)

PubMatic

Audio Video Media (2)

YouTube

Conversion & Analytics (2)

Google Analytics

Email Services (1)

Microsoft Exchange Online

More Technologies

6

See all

News & Signals from Acelyrin, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAlumis Inc. partnered with Acelyrin, Inc on Feb 6th '25.On February 6, 2025, Alumis Inc. announced a merger agreement with ACELYRIN, Inc., creating a combined company dedicated to developing transformative therapies for immune-mediated diseases.

NewsGil Labrucherie left Acelyrin, Inc as Chief Financial Officer on Jan 2nd '24.Acelyrin said that Chief Financial Officer Gil Labrucherie has resigned and will be leave on Jan. 2 to pursue another opportunity.

NewsAcelyrin, Inc is developing transformative medicines in immunology, with a lead program targeting thyroid eye disease.ACELYRIN, INC. is a late-stage clinical biopharmaceutical company that focuses on developing transformative medicines in immunology, with a lead program targeting thyroid eye disease.